Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depemokimab - GSK

Next Previous
Drug Profile

Depemokimab - GSK

Alternative Names: AQ82742999; GSK 294; GSK-3511294

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Asthma; Rhinosinusitis
  • Phase III Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Hypereosinophilic syndrome

Most Recent Events

  • 17 Sep 2025 GlaxoSmithKline plans phase-III VIGILANT trial for Chronic obstructive pulmonary disease (In adults, In the elderly, Adjunctive treatment) in November 2025 (SC) (NCT07177339)
  • 23 Jun 2025 GlaxoSmithKline initiates the phase III ENDURA-2 trial in Chronic obstructive pulmonary disease (In the elderly, In adults, Adjunctive treatment) in USA (SC) (NCT06961214)
  • 20 Jun 2025 Phase-III clinical trials in Chronic obstructive pulmonary disease (In the elderly, In adults, Adjunctive treatment) in USA (SC) (NCT06959095)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top